Google Search

Search

Already a Member ?

Best Business Opportunities in Saint Helena, Africa- Identification and Selection of right Project, Thrust areas for Investment, Industry Startup and Entrepreneurship

We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 18 of 56 | Total 558 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 55 56   Next »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Market Research Report on Medical Devices & Disposables Industry in India (Disposable Plastic Syringes, Disposable Mask & Gloves, Blood Bags, X-Ray, Ultrasound, ECG, Pacemakers, IV Fluid Sets and Other Devices) Outlook and Forecasts Up to 2023

Market Research Report on Medical Devices & Disposables Industry in India (Disposable Plastic Syringes, Disposable Mask & Gloves, Blood Bags, X-Ray, Ultrasound, ECG, Pacemakers, IV Fluid Sets and Other Devices) Market Analysis, Trends & Opportunities, Growth Drivers, SWOT Analysis, Industry Size, Outlook and Forecasts Up to 2023 The market research report titled ‘‘Medical Devices Industry in India (Disposable Plastic Syringes, Disposable Mask & Gloves, Blood Bags, X-Ray, Ultrasound, ECG, Pacemakers, IV Fluid Sets and Other Devices) Market Analysis, Trends & Opportunities, Growth Drivers, SWOT Analysis, Industry Size, Outlook and Forecasts Upto 2023’’ released by Niir Project Consultancy Services, provides a comprehensive analysis of Indian medical devices industry. The report begins by giving an overview of the global medical device industry mentioning the global market size of the industry. It further moves to analyse the Indian scenario by citing information like structure and classification of the sector. Despite a high demand for medical devices, India depends heavily on imports of devices to meet domestic demand. It imports ~80% of the devices required. The last few years have seen an increase in domestic manufacturing of medical equipment backed by strong governmental support. Related Projects: - Surgical, Medical Plastics, Medical Disposables, Disposable Medical Products used in Hospitals The report analyses the medical devices sector in profundity by covering data points like industry growth drivers, emerging trends coupled with SWOT analysis of the market and the regulatory framework. The report scrutinizes the potential of the sector by way of measuring its growth drivers. Indian medical device industry is poised for significant growth in coming years backed by factors like booming medical tourism, rising health awareness among Indian populace, growing incidence of lifestyle diseases and the growth of healthcare services in India. Indian medical device industry though dominated by imports has immense potential for growth for industry players to tap. Growing health insurance sector in the country is a key indicator of rising health awareness among Indians. Although India remains as one of the least insured nations in the world, the health insurance penetration is rising gradually. Rising disposable household income, awareness around health and rising lifestyle ailments plaguing Indians are some of the causes driving the demand for medical devices in the country. Indian medical devices industry has been in the limelight recently due to increased government focus on encouraging the domestic production in the industry. Indian government has announced a heavy package over various schemes to uplift the industry. Related Books: - Disposable Products (Medical, Surgical, Thermocol, Plastic, Paper, Domestic And General Products) Some of the trends hitting the sector are rising usage of home care devices, remote patient monitoring devices, unprecedented demand for disposables and use of refurbished equipment. India has been experiencing winds of change with the changing cultural attitudes and the millennial consumer. High levels of stress lack of work-life balance and growing need for real time monitoring are some contributing factors to a mounting demand for home healthcare. Also, due to current COVID-19 pandemic situation, India has seen unprecedented growth in the demand and usage of medical disposables such as face masks and gloves. To encourage the domestic production of medical devices in the country, government has announced various schemes supporting the growth of the sector. Related Videos: - Industrial, Medical and Specialty Gases Manufacturing Project Ideas The report further scrutinizes the industry with the help of SWOT Analysis. Growing Indian population, favourable demographics and recession proof nature of the industry are some of the strengths of the industry. Indian population has been growing at a steady rate which ensures stable demand for medical devices in India. The growth of the healthcare sector in the last decade has been phenomenal majorly driven by Indian demographics, rising incomes, growing health awareness and increased government focus on improving healthcare situation in India. Medical devices industry constitutes ~4-5% of the overall healthcare industry and is a direct beneficiary of any growth in the healthcare sector. Similarly, change in the Indian demographic situation is another positive factor for the industry’s growth. Indian market offers immense opportunities for sector to tap in terms of rising incomes, escalating government spending on healthcare and low penetration of medical devices in the country. The medical device penetration in India is extremely low which serves as a massive opportunity for the device companies. Plan outlay for healthcare sector has increased from INR 500 billion in 2017-18 to INR 690 billion in 2020-21. Such increased government focus on healthcare puts Indian medical devices industry in a sweet spot. Industry faces challenges from stiff competition from the existing players and also from heavy dependency of industry on imports. The industry although being a high potential industry is bogged down by its high capital requirements. Indian medical device industry is capital intensive by nature and setting up a manufacturing plant requires significant investment. Indian medical device industry, being a part of healthcare industry, is plagued by all the challenges and weaknesses of its giant mother industry. The healthcare situation in India is not very encouraging when compared to other parts of the world and it remains one of the biggest challenges for the Indian medical device industry. Even though India offers the most affordable healthcare services globally, yet the treatment for its own population remains inaccessible and unaffordable to quite an extent. The report further expounds the domestic demand/supply situation of the industry along with the international trade scenario. Indian imports of medical devices have been growing at a CAGR of ~13% during 2016-20. Indian exports of medical devices grew from INR 82 billion in 2016 to INR 127 billion in 2019, thus registering a CAGR of over 15% during this time. The report further provides financial information of the key players in the segment. Indian medical devices industry, though small, has been growing tremendously in the past few years. Favourable Indian demographics, rising incomes coupled with encouraging government initiatives and rising disease patterns in the country augurs well for the industry as a whole. India, with its large population base and increasing health awareness among its populace, offers a valuable and incomparable opportunity for the medical devices segment. Indian medical device industry is poised for significant growth in coming years. The market size of the Indian medical device industry stood at INR 339 billion in 2017 and is expected to reach new levels by 2023. Key Words: Medical Devices Industry ,disposable Plastic Syringes, Disposable Mask & Gloves, Blood Bags, X-Ray, Ultrasound, ECG, Pacemakers, IV Fluid Sets, surgical devices, surgical gloves, import, export, healthcare sector, healthcare services, hospital sector, medical tourism, homecare devices, medtech devices, public spending, healthcare penetration, recession proof, The Medical Devices (Amendment) Rules 2020, CDSCO, DCGI, CDA, ventilators, PPE coveralls, PPE kits, Production Linked Incentive (PLI) Scheme, Promotion of Medical Device Parks, hospital beds, cancer incidents, diabetes patients, lifestyle diseases, health insurance premium, health insurance penetration, health awareness, medical tourists, favorable demographics, Urbanization, market outlook, Diagnostic imaging, disposables, IV Diagnostics, Dental products, orthopaedic & Prosthetics, Patient Aids, HINDUSTAN SYRINGES & MEDICAL DEVICES LTD, Opto Circuits, Wipro GE Healthcare, Market Research Reports, India and Global Industry Analysis ,Market Trends, Market Insight, Market structure, Market outlook Indian Industry Size, Share, Trends, Analysis and Forecasts report, sector Growth Driver, company profiles, key financials, ratios #Healthcare #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #businessstartupindia #MarketReseach #businessplans #projectconsultancy #BusinessFeasibilityStudies #technologyindustry #businessplanning
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Active Pharmaceutical Ingredient (API), is the term used to refer to the biologically active component of a drug product (e.g. tablet, capsule). Drug products are usually composed of several components. The aforementioned API is the primary ingredient. Other ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components used in the drug is known as "formulation." India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Dr. Reddy'S Laboratories Ltd. Glaxosmithkline Pharmaceuticals Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd.
Plant capacity: Paracetamol:1,000 Kgs / day Azithromycin:500 Kgs / day Amoxicillin Trihydrate:500 Kgs / dayPlant & machinery: Rs 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

E-Waste Recycling Plant

Electronic wastes, "e-waste", "e-scrap", or "Waste Electrical and Electronic Equipment" ("WEEE") is a description of surplus, obsolete, broken or discarded electrical or electronic devices. Technically, electronic "waste" is the component which is dumped or disposed or discarded rather than recycled, including residue from reuse and recycling operations. Because loads of surplus electronics are frequently coming led (good, recyclable, and non-recyclable), several public policy advocates apply the term "e-waste" broadly to all surplus electronics. Electronic Waste – or e-waste – is the term used to describe old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc. which have been disposed of by their original users. While there is no generally accepted definition of e-waste, in most cases, e-waste comprises of relatively expensive and essentially durable products used for data processing, telecommunications or entertainment in private households and businesses. The rising levels of e-waste generation in India have been a matter of concern in recent years. With more than 100 crore mobile phones in circulation, nearly 25 per cent end up in e-waste annually.“India has surely emerged as the second largest mobile market with 1.03 billion subscribers, but also the fifth largest producer of e-waste in the world, discarding roughly 18.5 lakh metric tonnes of electronic waste each year, with telecom equipment alone accounting for 12 per cent of the e-waste’’. The fastest growing sources of waste and is estimated to be increasing by 16-28 per cent every five years. Within each sector a complex set of heterogeneous secondary wastes is created. Although treatment requirements are complicated, the sources from any one sector possess many common characteristics. However, there exist huge variations in the nature of electronic wastes between sectors, and treatment regimes appropriate for one cannot be readily transferred to another. E-Waste or Electronic Waste broadly describes loosely discarded, surplus, broken, obsolete, electrical and electronic devices. E-Waste is an area of immediate and long-term concern as its unregulated accumulation and recycling can lead to major environmental degradation which will pose a major threat to human health. Revolution of IT, new and innovative technologies and globalization of economy have made new electronic products available and affordable. But on the other hand, it has also led to unrestrained resource consumption and E-Waste generation. Electronic waste (e-waste) typically includes discarded computer monitors, motherboards, mobile phones and chargers, compact discs, headphones, television sets, air conditioners and refrigerators. According to the Global E-Waste Monitor 2017, India generates about 2 million tonnes (MT) of e-waste annually and ranks fifth among e-waste producing countries, after the US, China, Japan and Germany. In 2016-17, India treated only 0.036 MT of its e-waste. About 95 per cent of India’s e-waste is recycled in the informal sector and in a crude manner. Only 20 per cent of global e-waste is recycled. The market in Asia-Pacific has been categorized as China, Japan, India, and the rest of Asia-Pacific. The market in Asia-Pacific is expected to register the highest CAGR of 15.25% during the forecast period. Japan is expected to be a leading country-level market and is expected to register a 12.75% CAGR. India is expected to be the fastest-growing country-level market, expected to register the highest CAGR over the next few years. This is due to the growing population in the region. Also, growing awareness of e-waste recycling and government initiatives are the major factors for the growth of the market. India is emerging as one of the world's major electronic waste generators, posing grave concerns to public health and environment alike.Industry body Assocham, said India’s ‘production’ of e-waste is likely to increase by nearly three times, from the existing 18 lakh metric tons (MT) to 52 lakh MT) per annum by 2020 at a compound annual growth rate (CAGR) of about 30%.The Global Electronic Waste Recycling Market is expected to expand at 13.03% CAGR to reach a market value of 39,498.81 Million in 2024. A mere 1.5% of India's total e-waste gets recycled due to poor infrastructure, legislation and framework which leads to a waste of diminishing natural resources, irreparable damage of environment and health of the people working in industry. Over 95% of e-waste generated is managed by the unorganized sector and scrap dealers in this market, dismantle the disposed products instead of recycling it. Few Indian major players are as under E-ParisaraaPvt Ltd Attero India Pvt Ltd, E-waste Recyclers India, Eco Recycling Limited (ECORECO), Hi-Tech Recycling India Pvt. Ltd., Ultrust Solutions Pvt. Ltd.,
Plant capacity: Aluminium : 3 MT / day Mild Steel: 2 MT / day Shredded PCB: 15.00 MT / dayPlant & machinery: Rs 88 lakhs
Working capital: -T.C.I: Cost of Project: Rs 533 lakhs
Return: 29.00%Break even: 59.00%
Add to Inquiry Add to Inquiry Basket

Market Research Report on India Active Pharmaceutical Ingredient (API)

Market Research Report on India Active Pharmaceutical Ingredient (API) Market, Growth Rate, Covid-19 Impact, Economic Impact, Size, Share, Trend, Drivers, Competitive Landscape, Opportunity, Limitations, Technological Landscape, Regulatory Framework, PESTEL Analysis, PORTER’s Analysis, Forecast upto 2027 Market by Manufacturing Process (Captive Manufacturing, Contract Manufacturing), By Type of Synthesis (Synthetic, Biotech), By API Formulation (Generic API, Innovative API), By Application (Cardiovascular Disease & Hematopoietic System, Central Nervous System, Anti-infectives, Respiratory, Gastrointestinal Disorders, Urology, and Others and By Region (North India, South India, West India, and East India) The India API Market is expected to Drive Owing to the R&D Activities and Surge in the Incidence of Chronic Disease The India API market projected to reach USD 27.49 billion at a significant CAGR of over 10.23% during the forecasted period of 2020-2027. Due to the rising up gradation of technology across India and the growing incidence of hereditary cardiac disease, it is further projected to accelerate the API market at a significant rate across the country. Furthermore, the propelling focus on precision medicine is precited to accelerate the India active pharmaceutical ingredient market. Moreover, the use of drug development techniques focused on Artificial Intelligence further expected to boost the market. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Additionally, strategic outsourcing enables enterprises to rely on their core competencies, contributing to improved efficiency, which is anticipated to fuel India's API market. Furthermore, the rising demand for biosimilars across India is predicted to drive the market at a considerable rate. However, the lack of skilled labor is predicted to challenge the growth of the market. Additionally, the increasing penetration of counterfeit drugs further projected to hinder the Indian market's growth substantially. Manufacturing Process Overview in the India API Market Based on the manufacturing process, the India API market segregated into Captive Manufacturing and Contract Manufacturing. The Captive Manufacturing segment is predicted to hold the largest share during the forecasted period of 2020-2027 across the country. It is attributed to the proper manufacturing and strong capitalization of raw materials, which is estimated to boost the India API market significantly. In addition, manufacturing technologies favor in-house production of innovative products to take advantage of the economic opportunities and avoid the proliferation of technologies, which is further predicted to accelerate the market. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Type of Synthesis Overview in the India API Market Based on the type of synthesis, the India API market is segregated into Synthetic and Biotech. The biotech segment is estimated to have the fastest growth rate during the forecasted period of 2020-2027 owing to the propelling technological advancement in the manufacturing process. Additionally, the increasing demand for the therapeutic and diagnostic solution on Red Biotechnology concepts, recombinant, and DNA sequencing technology is anticipated to boost the market. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs API Formulation Overview in the India API Market Based on the API Formulation, the India API market is categorized into Generic API and Innovative API. The Generic API segment is predicted to hold the largest share over the forecasted period of 2020-2027 across the country. It is attributed to the patent expiry of labeled molecules, which is expected to drive the market at a considerable growth rate. In addition, the decreased in the cost of the generic drug is further projected to fuel the India API market. Related Market Research Report: - India Active Pharmaceutical Ingredient (API) Market However, the Innovative API segment is estimated to have a significant growth rate during the forecasted period by 2027 due to the presence of favorable government regulations in the research and development of drugs. Application Overview in the India API Market Based on the Application, the India API market is classified into Anti-infectives, Cardiovascular and Hematopoietic System, Central nervous system, Respiratory, Gastrointestinal Disorders, Urology, and Others. The Cardiovascular and Hematopoietic System segment is expected to hold significant market share in API market over the forecasted period of 2020-2027 across the country due to the increasing prevalence of cardiovascular diseases coupled with the incidence surge of obesity. In addition, the variation in lifestyle has increased the incidence of obesity is further predicted to drive the segment's market. Projects: - Project Reports & Profiles However, the Central nervous system segment is expected to have a considerable growth rate during the forecasted period by 2027 across the country. It is due to the increasing emphasis on early diagnosis & treatment, which is predicted to fuel the market. Additionally, the growing prevalence of neurological diseases and rising funding for neurological diagnostics is estimated to improve the market significantly. Regional Overview in the India API Market By geography, the India API market segmented into North India, South India, West India, and East India. The West India region is projected to hold the largest share during the forecasted period of 2020-2027 owing to technological advancement. In addition, rapidly evolving healthcare facilities and growing healthcare budgets are further anticipated to propel the India API market. Furthermore, the availability of affordable labor across the region is expected to accelerate the region's market. Books: - BOOKS & DATABASES India API Market: Competitive Landscape Companies such as Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Sun Pharmaceutical Industries Limited, GlaxoSmithKline Pharmaceuticals Ltd, Indoco Remedies Ltd., Piramal Enterprises Ltd., Teva Pharmaceutical & Chemical Industries India Pvt. Ltd., Sri Krishna Pharmaceuticals Limited, Pan Drugs Limited, and Other Prominent Players are the key players in the India API market. Tags #MarketResearchReports #MarketReseach #IndustryTrends #IndustryDemands #ActivePharmaceuticalIngredient #API #pharmaceutical #pharmaceuticalindustry #NPCS #projectconsultancy #businessconsultancy #apimarket #chemicalapimarket #biotechapimarket #highpotencyapi #marketforecast #GlobalMarket #GrowthRate #MarketTrend #marketdrivers #marketopportunity #marketanalysis #PESTELAnalysis #MarketEconomic #MarketSize #MarketShare #MarketGrowthRate #markettrends #MarketImpact #marketDemand #MarketStrategy #Marketinvestment #marketinggrowth
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol)

The Active Pharmaceutical Ingredient (API) is the part of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to cut costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Cefalexin, is an antibiotic that can treat a number of bacterial infections. It kills gram-positive and some gram-negative bacteria by disrupting the growth of the bacterial cell wall. Cefalexin is a beta-lactam antibiotic within the class of first-generation cephalosporins. It works similarly to other agents within this class, including intravenous cefazolin, but can be taken by mouth. Cefalexin can be used in those who have mild or moderate allergies to penicillin. However, it is not recommended in those with severe penicillin allergies. Ampicillin is an antibiotic used to prevent and treat a number of bacterial infections, such as respiratory tract infections, urinary tract infections, meningitis, salmonellosis, and endocarditis. It may also be used to prevent group B streptococcal infection in newborns. It is used by mouth, by injection into a muscle, or intravenously. Like all antibiotics, it is not useful for the treatment of viral infections. Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumoniae, Streptococcus pyogenes, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of action of is not known. Paracetamol is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint. Paracetamol is generally safe at recommended doses. The recommended maximum daily dose for an adult is three to four grams. Higher doses may lead to toxicity, including liver failure. Serious skin rashes may rarely occur. It appears to be safe during pregnancy and when breastfeeding. In those with liver disease, it may still be used, but in lower doses. It is classified as a mild analgesic. It does not have significant anti-inflammatory activity. How it works is not entirely clear. Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug (NSAID) class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. It can be used by mouth or intravenously. It typically begins working within an hour India's reliance on pharma ingredient imports has risen over the past few decades due to the higher cost of domestic production, with the price gap reaching as much as 20%-30%, particularly for energy-intensive fermentation-based ingredients used in anti-infectives. Import dependence is more than 90% for some life-saving drugs, including penicillin and ciprofloxacin. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. The country has a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one of the largest recipients of FDI in the world. Asia Pacific is expected to be the fastest-growing market over the forecast period. Owing to the availability of affordable labor, major companies in the market are setting up API manufacturing plants in developing countries such as China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd.
Plant capacity: Paracetamol: 500 Kgs / day Cephalexin: 500 Kgs / day Ampicillin Trihydrate: 500 Kgs / day Ibuprofen: 500 Kgs / dayPlant & machinery: Rs 347 lakhs
Working capital: -T.C.I: Cost of Project: Rs 1656 lakhs
Return: 36.00%Break even: 52.00%
Add to Inquiry Add to Inquiry Basket

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol.

API Production. Manufacturing of Active Pharma Ingredients (API), Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol. API (Active Pharmaceutical Ingredient) means the active ingredient which is contained in medicine. For example, an active ingredient to relieve pain is included in a painkiller. This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine. Related Projects:- Active Pharma Ingredients (api) The API form that is used in a formulation is often the most thermodynamically stable crystalline form. As such, the phenomenon of hydrogen bonding in combination with there being many functional groups on the API usually results in the available crystalline form being a hydrate. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Ampicillin is used to treat infections by many Gram-positive and Gram-negative bacteria. It was the first "broad spectrum" penicillin with activity against Gram-positive bacteria, including Streptococcus pneumonia, Streptococcus pyogenic, some isolates of Staphylococcus aureus (but not penicillin-resistant or methicillin-resistant strains), Trueperella, and some Enterococcus. Paracetamol is used for the relief of mild to moderate pain. The use of the intravenous form for short-term pain in people in the emergency department is supported by limited evidence. In adults it appears to be useful for migraines, tension headaches, perineal pain after childbirth, and kidney stone pain. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Ibuprofen is a medication in the nonsteroidal anti-inflammatory drug class that is used for treating pain, fever, and inflammation. This includes painful menstrual periods, migraines, and rheumatoid arthritis. It may also be used to close a patent ductus arteriosus in a premature baby. Market Outlook The production-linked incentive scheme - which accounts for INR0.9 billion of planned outlay - offers an incentive of up to 20% of sales for fermentation based products and up to 10% for chemical synthesis-based products for the next eight to nine years. This should help to bridge the price gap and make domestic production more competitive. The government has also allocated USD0.4 billion under the capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks. We believe this will aid the investment decisions of Indian pharma companies, particularly in the current environment where the focus in on conserving cash. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Active pharmaceutical ingredients are an active ingredient of any drug or tablet, which possesses medicinal properties. Some drugs with combined therapy have many active ingredients to treat different disorders. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Higher Growth in the APAC Active Pharmaceutical Ingredients Market Healthcare spending has witnessed continued growth for some time now. Even though the proportion of healthcare spending in the APAC region is comparatively low, the growth rate in this strategic region has outpaced that of mature markets in North America and Europe. Rising healthcare spending has led to quality healthcare becoming accessible along with a higher demand for pharmaceutical products across APAC. The pharmaceuticals consumed here are mostly produced in onshore manufacturing units. Furthermore, contract manufacturing organizations are key outsourcing allies for pharmaceutical companies that supply their wares to North America and Europe. Books:- BOOKS & DATABASES Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. Related Videos:- Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit The global active pharmaceutical ingredients market has been broadly segmented based on manufacturer, APIs, drug, therapeutic, and region. In terms of manufacturer, the global market has been classified into in-house API manufacturing and API contract manufacturing. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Videos:- Manufacturing Business Ideas in Pharmaceutical Industry Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. Related Projects:- Startup Opportunities in Active Pharma Ingredients The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. Market Research Reports:- India Active Pharmaceutical Ingredient (API) The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Market Research:- Market Research Reports Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Related Projects: - Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Related Projects:- Active Pharma Ingredients (api) (cephalexin, Ampicillin Trihydrate, Ibuprofen And Paracetamol) Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Related Projects: - Active Pharma Ingredients (API) Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Projects: - Project Reports & Profiles For More Details, Click Here: - Key players Alpha Remedies Ltd. Ankur Drugs & Pharma Ltd. Aurobindo Pharma Ltd. Cian Healthcare Ltd Cipla Ltd. Dr. Reddy'S Laboratories Ltd. Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Indoco Remedies Ltd. Pan Drugs Ltd. Piramal Enterprises Ltd. Sanofi India Ltd. Sri Krishna Pharmaceuticals Ltd. Teva Pharmaceutical & Chemical Inds. India Pvt. Ltd. Triton Laboratories Ltd. For More Details, Click Here: - https://bit.ly/32McBPb Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Disposable Surgical Mask Production. Investment and Business Opportunities in Medical Disposable Industry.

Disposable Surgical Mask Production. Investment and Business Opportunities in Medical Disposable Industry. Face masks are one tool utilized for preventing the spread of disease. They’ll even be called dental, isolation, laser, medical, procedure, or surgical masks. Face masks are loose-fitting masks that cover the nose and mouth, and have ear loops or ties or bands at the rear of the top. There are many various brands and that they are available different colors. It’s important to use a mask approved by the FDA. Related Projects:- Disposable Surgical Masks A surgical mask, also referred to as a face mask, is meant to be worn by health professionals during healthcare procedures. It’s designed to stop infections in patients and treating personnel by catching bacteria shed in liquid droplets and aerosols from the wearer's mouth and nose. They’re not designed to guard the wearer from breathing in airborne bacteria or viruses whose particles are smaller. With reference to some infections like influenza they seem as effective as respirators, such as N95 or FFP masks though the latter provide better protection in laboratory experiments because of their material, shape and tight seal. Related Books:- Disposable Products (Medical, Surgical, Thermocol, Plastic, Paper, Domestic And General Products) - Use And Throw Items, Single Use Items, Disposable Take-Away Packaging, Disposable Items Manufacturing Uses Disposable face masks are medical supplies that are worn to cover the mouth and nose and prevent people from inhaling poisonous airborne substances or other impure substances. Alternatively, it also is a shield against ill people that may unintentionally spread illnesses via the contaminants which may begin of their mouth. Generally, in medical health care centre, disposable face masks are wont to prevent the spread of infections from patients who are sick. The masks are quite effective when the patient comes in touch with people. However, facemasks also are worn by the hospital staff and employees working in medical healthcare institutions because they frequently affect different sorts of patients having varied varieties of diseases. Research Report: - Market Research Report Disposable face masks are known by different names. A number of these terms are surgery masks, medical procedure masks, and laser and isolation masks. Face masks are available in different shapes and sizes alongside varied densities of thickness. The thickness of the mask significantly affects the breathing capabilities of the person wearing it. If the thickness of the mask is high, then it'll make the breathing difficult. Which is why, at times, people with affected by asthma and emphysema may need to consult a doctor before wearing face masks. Related Videos: - Manufacturing of Medical Disposable Face Masks. How are Surgical Masks Made? Surgical face masks are made with non-woven fabric, which has better bacteria filtration and air permeability while remaining less slippery than woven cloth. The material most commonly used to make them is polypropylene, either 20 or 25 grams per square meter (gsm) in density. Masks can also be made of polystyrene, polycarbonate, polyethylene, or polyester. Project Identification 20 gsm mask material is made in a spun bond process, which involves extruding the melted plastic onto a conveyor. The material is extruded in a web, in which strands bond with each other as they cool. 25 gsm fabric is made through melt blown technology, which is a similar process where plastic is extruded through a die with hundreds of small nozzles and blown by hot air to become tiny fibers, again cooling and binding on a conveyor. These fibers are less than a micron in diameter. Related Projects:- Surgical, Medical Plastics, Medical Disposables, Disposable Medical Products used in Hospitals Surgical masks are made up of a multi-layered structure, generally by covering a layer of textile with non-woven bonded fabric on both sides. Non-woven, which are cheaper to make and cleaner thanks to their disposable nature, are made with three or four layers. These disposable masks are often made with two filter layers effective at filtering out particles such as bacteria above 1 micron. The filtration level of a mask, however, depends on the fiber, the way it’s manufactured, the web’s structure, and the fiber’s cross-sectional shape. Masks are made on a machine line that assembles the nonwovens from bobbins, ultrasonically welds the layers together, and stamps the masks with nose strips, ear loops, and other pieces. Completed masks are then sterilized before being sent out of the factory. Related Books: - Handbook on Medical and Surgical Disposable Products Market Outlook Indian market Surgical masks are disposable devices that cover the mouth and nose during medical procedures. They prevent the spread of infection between diseased and healthy population. Surgical masks are typically used in a health facility (hospitals, emergency departments, out-patient facilities, residential care facilities, emergency medical services) and home health care delivery. The India surgical mask market was valued at $71.73 million in 2019, and is expected to reach $157.13 million by 2027, registering a CAGR of 10.3% from 2020 to 2027. Related Video: - Production of Disposable Surgical and Medical Face Mask However, surgical disposables like masks, contain absorbent chemicals and are discarded after use. Most of those masks are made from superabsorbent polymers like polyacrylate, which are non-biodegradable. These products contain quite 90% plastic with superabsorbent polymers and non-woven plastic components. Thus, the disposal issue of those masks has become an environmental hazard, which impedes the growth of the India surgical masks market. Similarly, increase in usage of less invasive surgeries is anticipated to decrease the utilization of surgical masks within the upcoming years. Minimally invasive surgeries are estimated to scale back the usage of surgical apparels like surgical masks, caps, and others in hospitals, during operative procedures. Additionally, the utilization of efficient robotics in surgical procedures is further anticipated to scale back the demand for protective apparels required by surgeons during medical procedures. Conversely, technological integration within the process of surgical masks making is predicted to make beneficial opportunities within the future. Advancements in production of reusable nonwoven products like antimicrobial fibers and improved comfort are expected to fuel the expansion of the India surgical masks market. Related Projects:- Disposable Products and Projects from Paper, Plastic, Thermocol, Banana Leaves (Use and Throw Items, Throwing Item, Single Use Items, Disposable Take-Away Packaging, Disposable Food Packaging, Disposable Items Manufacturing) Conversely, increase in concerns regarding the disposal of surgical masks and rise in popularity of lesser invasive surgeries are foreseen to impede the market growth in coming years. On the contrary, innovations in nanotechnology and its increased use in surgical mask production together with upsurge in demand for single use of nonwoven surgical mask are predicted to make remunerative opportunities for the India surgical masks market growth within the near future. Related Project Blog: - Blog Global Market Increasing need for improved safety standard has led to the rise within the growth of the surgical mask market as success rate of surgeries largely depends on the extent of safety and precautions taken during surgeries. Surgical mask are used as a barrier to avoid cross contamination by microorganisms and are used during surgical procedures. The surgical mask is used by surgeons during procedures and other medical professionals while interacting with the patients to avoid cross contamination of microorganisms. The patient who is under treatment also must be protected against infectious agents that's set to be discharged by others within the surgery rooms. Related Projects: - Healthcare and Medical Businesses The demand within the worldwide marketplace for surgical mask has been rising on account of advancements within the field of medical surgery and diagnosis. Surgical masks are meant to guard doctors and surgeons from harmful infections and pathogens which will get suspended within the surgery room. Furthermore, the patient who is under treatment also must be shielded from infectious agents which will be discharged by others within the surgery rooms. Hence, the worldwide marketplace for surgical mask is predicted to expand at a stellar pace within the years to follow. There are multiple attempts at manufacturing improved surgical masks, and this has given an impetus to plug growth. Projects:- Project Reports & Profiles The Global Disposable Face Masks Market size is expected to reach $91.3 billion by the end of 2020, rising at a market growth of 97.4% CAGR during the forecast period (2019-2025). Disposable face masks are widely prevalent among medical professionals, industry workers, sanitation personnel, laboratory workers, police and security personnel, airport security personnel, and the general public. These masks are practically worn by anyone who opts to add an extra safety precaution of hygiene and safety in their daily routine. The global disposable face masks market includes the type of face masks that are used for covering the nose and the mouth of the wearer for providing protection against contamination, infection, protection from potential viruses as well as foreign or harmful elements in the surrounding. Books:- BOOKS & DATABASES Key Players Key players operating in the India surgical masks market such as Thea-Tex Healthcare (India) Pvt. Ltd., Venus Safety & Health Pvt. Ltd., Magnum Health and Safety Private Limited, Z Plus Disposable, Salus Products, Smilepad Hygiene India Pvt. Ltd., Cartel Healthcare Pvt. Ltd., MBL Impex Private Limited, Medicare Hygiene Limited, Mediblue Health Care Private Limited., Plasti Surge Industries Pvt. Ltd., Medline Industries Inc., Premium Health Care Disposables Private Limited, Kwalitex Healthcare Private Limited, and 3M Company Tags:- #disposablesurgicalmasks #facemask #mask #surgicalmasks #SurgicalMaskProduction #Covid19Pandemic #SurgicalMaskMarket #medicalmasks #protectionmask #SafeFaceMask #disposablemask #cottonmasks #N95Mask #KN95Mask #COVID_19 #MedicalFaceMask #MedicalMask #3PlyFaceMask #3PlyMask #3LayerFaceMask #3LayerMask #COVID19 #DetailedProjectReport #businessconsultant #feasibilityReport #NPCS #BusinessPlan #startupideas #entrepreneurindia #startupbusiness #projectreport #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API),

Best Business Opportunity to Start Dairy Farming & Dairy Products, Groundnut Oil, Nicotine from Tobacco Waste, IV Fluids (BFS Technology), Disposable Nitrile Gloves, Toothpaste, Active Pharma Ingredients (API), Are you searching for manufacturing business ideas? If you have sizeable money to invest and a more risk-taking ability, starting a business is a good decision. Product manufacturers can generate new value, minimize costs, and increase operational stability by focusing and prioritizing on four broad areas: production, product design, value recovery, and supply-chain management. Thinking about stepping into manufacturing industry business, you need to consider the option of starting on a limited size production. Starting with the making of essential components of the various industries. Once you set up things well, you could choose to start an industry and gradually become the giant of the industry. Projects:- Project Reports & Profiles Get ready and quickly go through these top business ideas that are the best options available with high return on investment. Choose any of these high net profit margin ideas if you want to start a venture in the manufacturing industry. Becoming an entrepreneur easier than ever before—technology is shrinking the world, opening markets, and making it possible for many people to strike out on their own in the field of their dreams. An entrepreneur who starts his own business can break free from this actuarial perspective and redefine the value he brings to the market. Books:- BOOKS & DATABASES Dairy Farming & Dairy Products (Milk, Butter, Ghee & Paneer) Dairy farming may be a class of agriculture for long-term production of milk, which is processed for eventual sale of a dairy product. Dairying is a very important source of subsidiary income to small/marginal farmers and agricultural laborers. India derives nearly 33% of the gross Domestic population from agriculture and has 66% of economically active population, engaged in agriculture. The share of livestock product is estimated at 21% of total agriculture sector. Milk production alone involves over 70 million producers, each raising one or two cows/buffaloes primarily for milk production. Additionally to exploit, the manure from animals provides an honest source of organic matter for improving soil fertility and crop yields. The gobar gas from the dung is used as fuel for domestic purposes as also for running engines for drawing water from well. In Hinduism; cow urine features a special significance as a drink. Sprinkling of cow urine is said to possess a spiritual cleansing effect furthermore. Gomutra isn't a toxic industrial waste material. 95% of its water, 2.5% consists of urea, and therefore the remaining 2.5% may be a mixture of minerals, salts, hormones and enzymes. Related Projects:- Milk & Dairy Products The global dairy products market is expected to grow at a CAGR of 5.2% from 2019 to reach $645.8 billion by 2025. Dairy is defined as a business enterprise that deals with the processing and harvesting of animal milk for human consumption. Some of the common milch animals include cow, goat, buffalo, camel and sheep. The milk obtained from these animals can be consumed directly and processed into ice cream, cheese, paneer, butter, ghee, condensed milk and yogurt. These products offer various nutrients such as calcium, proteins, zinc, magnesium, and vitamin D and B12. With widespread demand for dairy products and their proactive function in the global food industry, dairy plays a crucial role in the growth of the economies worldwide. Over the years, the dairy industry has witnessed improvements in product safety through specialization, modernization and consolidation. Moreover, advancements in global trade have also influenced the profitability of dairy farms. Related Books:- Milk Processing, Dairy & Dairy Products, Poultry Industries As of 2018, India is the leading milk producing country in the world, accounting for ~19% of the global market share. The milk processing industry in India is expected to expand at a compound annual growth rate (CAGR) of ~14.8% between FY 2018 and FY 2023, and will reach INR 2,458.7 Bn in FY 2023. Groundnut Oil Groundnut oil may be a vegetable oil derived from groundnuts. It’s also called groundnut oil. The oil features a strong peanut flavor and aroma. It’s often utilized in American, Chinese, South Asian and Southeast Asian cuisine, both for general cooking, and within the case of roasted oil, for added flavor. Unrefined groundnut oil features a smoke point of 320°F/160°C and is employed as a flavor ant for dishes like sesame oil. Groundnut haulms are nutritious and widely used for feeding livestock. The groundnut oil consists of mixed glycerides, and contain a high proportion of unsaturated fatty acids, especially Oleic (50-56%) and Linoleic (18-30%). Related Projects: - Edible Oils Projects In India, groundnut is cultivated in 5.8 million hectares. Gujarat is that the highest producer of groundnut oil in India. Groundnut seed contains 50-55% of the oil. It’s one among the most effective oil seeds to extract oil from. Increasing use of groundnut oil in cosmetics are getting to be one altogether the primary drivers of the peanut oil market. The abrasive, volatizing, and cleansing properties of hot-pressed groundnut oil and its derivatives are boosting its application in BPC product and cosmetics, such as moisturizers and skin cleansers. Growing popularity of blended oil are getting to be one altogether the critical groundnut oil market trends. The utilization of cheap alternatives, similar to oil in blended oil makes it more affordable than conventional oil. These advantages can boost the popularity of homogenized groundnut oil and consequently fuel the growth of the groundnut oil market. Related Books:- Market Research Report on Edible Oils in India However, the high production cost of peanut oil is a major factor expected to restraint growth of the target market in the near future. In addition, high consumption of peanut oil results in various side effects in human health which is one of the major factors expected to hamper growth of the target market to a certain extent. Global peanut oil market is set to witness a steady CAGR of 4.25% in the forecast period of 2019- 2026. Nicotine from Tobacco Waste Nicotine may be a natural product of tobacco, occurring within the leaves of nicotiana tabacum during a range of 0.5 to 7.5% counting on variety. Nicotine is additionally found within the leaves of nicotiana rustica, in amounts of 2–14%; in Duboisia hopwoodii and in Asclepias syriaca. Nicotine may be a widely used stimulant and potent par sympathomimetic alkaloid that's naturally produced within the nightshade family of plants. It’s used for smoking cessation to alleviate withdrawal symptoms. Nicotine may be a widely used stimulant and potent para sympathomimetic alkaloid that's naturally produced within the nightshade family of plants. It’s used for smoking cessation to relieve withdrawal symptoms. Related Projects:- Tobacco, Pan Masala, Khaini, Gutkha, Supari, Zarda, Mouth Freshener The India Tobacco Board has authorized a 2020 Traditional FCV crop size of 90 million kilos. However, crop size is estimated at 96 million kilos. A grade spread consisting of 20 million kilos of bright, 25 million kilos of the medium, and 51 million kilos of low style tobacco. 90% of the crop is already harvested. The average market price is USD 2.10 for this year. Indian Tobacco Board has authorized an NLS 2020 crop size of 46 million kilos. However, a crop size 42 million kgs is anticipated which was transplanted in 17,000 hectares and 90% of the crop has been harvested. The average market price is expected to be USD 2.30 for this year. Related Books:- Agriculture, Agro Based, Bakery, Wood, Ice Cream, Corn, Tobacco And Tobacco Products IV Fluids (BFS Technology) Intravenous fluids are fluids which are intended to be administered to a patient intravenously, directly through the circulatory system. These fluids must be sterile to guard patients from injury, and there are variety of various types available to be used. Many companies manufacture packaged intravenous fluids, also as products which may be mixed with sterile water to prepare a solution for intravenous administration. Fluids are given when someone's body fluid volume falls. There are variety of things which may cause a drop by fluid volume. Vomiting and diarrhea are a classic example, which is why people are encouraged to drink fluids once they are sick, to stay their fluid volume stable. Another cause is blood loss, which causes problems both because people lose blood products, and because they experience a loss in fluid volume. Electrolyte levels within the blood also can become unstable as a result of rapid changes in fluid volume, during which case intravenous fluids are often used to restore the balance. Related Projects:- IV Fluids, I.V. solutions, Intravenous fluids The primary costumers for these manufacturing units are Hospitals, Clinics, Dialysis centers, Home care settings. The global Intravenous Fluid market size was valued at US$ 8,372.0 million in 2019 and is expected to witness a CAGR of 6.1% over the forecast period (2019 – 2027). The basic function of I.V. fluids is to replenish body fluids. It can also be used in the treatment of electrolyte metabolism, especially in severe cases, therapy of acid-base in balances, the volume substitution and volume replacement in surgery of accident victims suffering blood loss. It can be used as parenteral nutrition for severally ill and post-operative patients. Related Books:- BOOKS & DATABASES Disposable Nitrile Gloves Nitrile gloves are a kind of disposable gloves made up of synthetic rubber, this suggests there's no risk of latex allergies. They the foremost popular gloves type in our range and offer superior strength, dexterity and resistance to oils and aqueous chemicals as compared to vinyl or latex. For these reasons, they're often utilized in the medical, laboratory and manufacturing industries. Nitrile gloves are an excellent compromise between latex and vinyl. Our Blue Nitrile gloves offer protection from bodily fluids providing a barrier that forestalls infection, cross-infection or cross-contamination. Tests revealed that Nitrile gloves are three times more puncture-resistant than rubber gloves. Related Projects:- Disposable Products and Projects from Paper The Indian market for medical gloves is still evolving. While the global market is growing at a compound annual growth rate (CAGR) of two per cent, the Indian market is at seven per cent growth. Every day there is a new hospital or nursing home popping up in India, so the demand for medical gloves is expected to increase. Medical tourism is also driving the growth of this product category in our country. The market size therefore only for gloves in India is Rs 300 crore. In view of all this, there is a good scope to initiate small-scale rubber gloves manufacturing unit. The Global Rubber Gloves market is expected to grow at a CAGR of 8.5% between 2014 and 2022. The factors such as rising healthcare expenditure, increasing health threats and increasing hygiene awareness and healthcare regulations are driving the market growth. Related Video:- Production of Disposable Nitrile Gloves Nitrile gloves are preferred over latex gloves because they resist chemicals, including certain disinfectants such as chlorine. There is a high rate of allergies to latex and contact allergic dermatitis among health workers. Non powdered gloves are preferred to powdered gloves. Toothpaste Toothpaste may be a paste or gel to be used with a toothbrush to maintain and improve oral health and aesthetics. Since their introduction several thousand years ago, toothpaste formulations have evolved considerably - from suspensions of crushed egg shells or ashes to complex formulations with often over 20 ingredients. Among these are often compounds to combat dental caries, gum disease, malodor, calculus, erosion and dentin hypersensitivity. Furthermore, toothpastes contain abrasives to wash and whiten teeth, flavors for the aim of breathe freshening and dyes for better visual appeal. Effective toothpastes are people who are formulated for maximum bioavailability of their actives. This, however, are often challenging as compromises will need to be made when several different actives are formulated in one phase. Related Projects:- Hygiene Products, Essential Personal Hygiene Products The global toothpaste market is projected to grow at a CAGR of 6.1% during the forecast period. The toothpaste market was valued at USD 26.09 billion in 2018, and it is projected to reach USD 36.98 billion by 2024. Increasing dental problems among children and adults, due to poor eating habits, and the rise in popularity for herbal oral care products are the factors primarily driving the global toothpaste market. Related Video:- Startup Business Opportunities in Toothpaste The rapidly changing lifestyle, improper diet, including sugar-rich diets, and therefore the increased consumption of alcohol and tobacco have made oral health one among the main public health problems in almost every a part of the planet. The impact of oral diseases on people's everyday lives is subtle and pervasive, influencing food habits, sleep, rest, social roles, and almost every phase of the day. Collectively, oral diseases and disorders create substantial pain and suffering. Because of this, consumers across the planet have started paying immense attention to maintaining their oral health, which has led to a rise within the sales of toothpaste across the world. Active Pharma Ingredients (API) (Cephalexin, Ampicillin Trihydrate, Ibuprofen and Paracetamol) The Active Pharmaceutical Ingredient (API) is that the part of any drug that produces the intended effects. Some drugs, like combination therapies, have multiple active ingredients to treat different symptoms or act in several ways. Production of APIs has traditionally been done by the pharmaceutical companies themselves in their home countries. But in recent years many corporations have opted to send manufacturing overseas to chop costs. This has caused significant changes to how these drugs are regulated, with more rigorous guidelines and inspections put into place. Related Projects:- Active Pharmaceutical Ingredient (API) Products, Bulk API Manufacturing India is that the seventh largest country within the world and has the second highest population. It a parliamentary democratic variety of government and has abundant natural resources and sufficient oil reserves. The country features a huge skilled, English-speaking, and inexpensive labor force. Its young population and current economic policies have made it one among the most important recipients of FDI within the world. Asia Pacific is predicted to be the fastest-growing market over the forecast period. Because of the supply of affordable labor, major companies within the market are setting up API manufacturing plants in developing countries like China and India. The global demand of APIs include ageing population, rising expenditures on healthcare, increasing prevalence of lifestyle diseases, etc. Looking forward, the market value is projected to reach US$ 258.8 Billion by 2025, exhibiting a CAGR of 5.6% during 2020-2025. The API market is competitive in nature and is becoming increasingly competitive. Consequently, manufacturers are required to enhance products in order to gain advantage over previously marketed products. Related Book:- India Active Pharmaceutical Ingredient (API) Market The government also notified a scheme to promote bulk drug parks. For selected parks, financial assistance to the tune of 70 per cent of the project cost of common infrastructure facilities will be provided. In the case of Northeast states and hilly states (Himachal Pradesh, Uttarakhand, Union Territory of Jammu & Kashmir, and Union Territory of Ladakh), financial assistance will be 90 per cent of the project cost. The maximum assistance under the scheme for one bulk Drug Park will be limited to Rs 1,000 crore. The total financial outlay of the scheme is Rs 3,000 crore. Tags:- #dairy #dairyfarming #DairyProducts #dairyindustry #GroundnutOil #Nicotine #tobaccowaste #IVFLUIDS #disposablenitrilegloves #disposablegloves #toothpaste #toothpastebusiness #hygieneindustry #ToothpasteIndustry #ToothpasteMarket #ToothpasteProject #activepharmaingredients #API #apimanufacturing #Apiproduction #ActivePharmaceuticalIngredient #pharmaceuticalindustry #apimarket #businessconsultant #businessfeasibilityreport #DetailedProjectReport #EntrepreneurIndia #startupideas #NPCS
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

E-Waste Recycling Plant

Electronic wastes, "e-waste", "e-scrap", or "Waste Electrical and Electronic Equipment" ("WEEE") is a description of surplus, obsolete, broken or discarded electrical or electronic devices. Technically, electronic "waste" is the component which is dumped or disposed or discarded rather than recycled, including residue from reuse and recycling operations. Because loads of surplus electronics are frequently coming led (good, recyclable, and non-recyclable), several public policy advocates apply the term "e-waste" broadly to all surplus electronics. Electronic Waste – or e-waste – is the term used to describe old, end-of-life electronic appliances such as computers, laptops, TVs, DVD players, mobile phones, mp3 players etc. which have been disposed of by their original users. While there is no generally accepted definition of e-waste, in most cases, e-waste comprises of relatively expensive and essentially durable products used for data processing, telecommunications or entertainment in private households and businesses. The rising levels of e-waste generation in India have been a matter of concern in recent years. With more than 100 crore mobile phones in circulation, nearly 25 per cent end up in e-waste annually. “India has surely emerged as the second largest mobile market with 1.03 billion subscribers, but also the fifth largest producer of e-waste in the world, discarding roughly 18.5 lakh metric tonnes of electronic waste each year, with telecom equipment alone accounting for 12 per cent of the e-waste’’. The fastest growing sources of waste and is estimated to be increasing by 16-28 per cent every five years. Within each sector a complex set of heterogeneous secondary wastes is created. Although treatment requirements are complicated, the sources from any one sector possess many common characteristics. However, there exist huge variations in the nature of electronic wastes between sectors, and treatment regimes appropriate for one cannot be readily transferred to another. The ‘Electronic Waste Management in India,’ conducted to mark World Environment Day, said as Indians become richer and spend more on electronic items and appliances, computer equipment accounts for almost 70% of e-waste material, followed by telecommunication equipment (12%), electrical equipment (8%) and medical equipment (7%). Other equipment, including household e-crap account for the remaining 4%. India is emerging as one of the world's major electronic waste generators, posing grave concerns to public health and environment alike. Industry body Assocham, said India’s ‘production’ of e-waste is likely to increase by nearly three times, from the existing 18 lakh metric tons (MT) to 52 lakh MT) per annum by 2020 at a compound annual growth rate (CAGR) of about 30%.The Global Electronic Waste Recycling Market is expected to expand at 13.03% CAGR to reach a market value of 39,498.81 Million in 2024. A mere 1.5% of India's total e-waste gets recycled due to poor infrastructure, legislation and framework which leads to a waste of diminishing natural resources, irreparable damage of environment and health of the people working in industry. Over 95% of e-waste generated is managed by the unorganized sector and scrap dealers in this market, dismantle the disposed products instead of recycling it. The market in Asia-Pacific has been categorized as China, Japan, India, and the rest of Asia-Pacific. The market in Asia-Pacific is expected to register the highest CAGR of 15.25% during the forecast period. Japan is expected to be a leading country-level market and is expected to register a 12.75% CAGR. India is expected to be the fastest-growing country-level market, expected to register the highest CAGR over the next few years. This is due to the growing population in the region. Also, growing awareness of e-waste recycling and government initiatives are the major factors for the growth of the market.
Plant capacity: Plastic Granules: 470 Kgs / Day Glass Scrap: 353 Kgs / Day Copper Scrap: 294 Kgs / Day Precious Metals (Nickel, Tin & Zinc): 60.00 Kgs / Day Gold : 0.0192 Kgs / Day Silver: 0.0384 Kgs / Day Palladium: 0.0010 Kgs / DaPlant & machinery: Rs 107 lakhs
Working capital: -T.C.I: Cost of Project : Rs 336 lakhs
Return: 28.00%Break even: 58.00%
Add to Inquiry Add to Inquiry Basket

Aqua Fish Feed

The fish culture has undergone a dramatic worldwide growth in the last few years. The aquaculture industry is the fastest growing food production industry in the world and approximately 50% of all fish consumed by humans is from aquaculture. Nutrition plays a vital role in improving animal productivity. Understanding about the nutritional requirements and production of fish feed is essential to the development and sustainability of aquaculture as the industry has matured. Prepared or artificial diets may be either complete or supplemental. Complete diets supply all the ingredients, protein (18-50%), lipid (10-25%), carbohydrate (15-20%), ash (<8.5%), phosphorus (<1.5%), water (<10%), and trace amounts of vitamins, and minerals necessary for the optimal growth and health of the fish. Fish feed are placed in the middle of the aquaculture value chain. Raw materials of marine or land based origin are mixed with other important ingredients to feed pellets, which through their transformation in the fish are important for the final quality of the fresh fish or the processed fish products for the consumers. Fish farmers in India have increased access to high-quality feed this year, as Cargill has opened its first feed plant dedicated to fish species in the country .The plant, located in Vijayawada and acquired from Mulpuri Foods & Feeds, reflects the company’s commitment to bring farmers safe, high-quality aqua feed solutions, according to a press release. It marks an important step in Cargill’s work to develop its aqua feed business in India and across Asia. Feed processing plant sell feed mainly in the forms of distributor and dealer, breeding enterprise directly purchase feed from the pant. Feed pants are also exploring ways to increase sales and market share with discounts. In India, feed can be sold on credit, if in a large amount of credit, many small feed enterprises are faced with a loss, and considering to sell the factory, only large feed enterprise with strong source of funds can survive. The price is different between credit and cash, the retail price of per kg Southern white leg shrimp is about $1.1-$1.4. Farmers pay cash to buy feed can have a discount of 10-15%. India has become the world’s second major aquaculture countries, the annual growth rate of aquaculture production will reach 8% in the next 5 years, and floating expanded feed system is gradually combined with aquaculture technology. In addition to ensuring sustainable development of the aquaculture industry, using of floating expanding fish feed can make the fish grow faster, be higher yield, higher feed conversion rate and economic efficiency than the traditional feeding mode. The India Aquaculture Feed Market was valued at USD 1.20 billion in 2017 and is expected to register a CAGR of 10.4% during the forecast period (2018-2023). India feed mills have the capacity to produce 2.88 million metric ton. Andhra Pradesh is the largest feed consuming state in India. The coastal line of the country is about 7,517 kilometers with 195.20 kilometers of river and canal systems. The country consists of 14 rivers, 44 medium rivers, and many small rivers. The country also has tanks and ponds. By these sources, it is clear that the aquaculture industry is huge in India which provides huge opportunity and potential for aquaculture feed industry. Increase in consumption of seafood and rising per capita income are the factors driving the growth of the aqua feed market. Seafood is a good source of vitamins and minerals which helps in maintaining nutrient diet. As seafood is free from harmful carbohydrates, it protects humans from heart diseases. With the flourishing seafood business and additional demand from domesticating acquitting animals, we have a profitable aqua feed market. As per our recent business intelligence report, the global aqua feed market size was $44.2 billion to $44.6 billion as of 2018, and the market demand is projected to increment at a healthy CAGR of 4% to 6% over the forecast period of 2019 to 2025. Few Indian major players are as under Waterbase Ltd. Taiyo Feed Mill Pvt. Ltd. Somkan Marine Foods Ltd. Rasoya Proteins Ltd. Mulpuri Foods & Feeds Pvt. Ltd. Growel Feeds Pvt. Ltd. Kwality Feeds Ltd
Plant capacity: Fish Feed: 60 MT / Day Prawn Feed: 60 MT / DayPlant & machinery: Rs 845 lakhs
Working capital: -T.C.I: Cost of Project: Rs 1702 lakhs
Return: 27.00%Break even: 55.00%
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 18 of 56 | Total 558 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 55 56   Next »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top